Xoma Corp. will sell an undisclosed amount of its common stock and warrants, the Berkeley antibody drug developer said Monday.
Xoma (NASDAQ: XOMA) will use money from the sale to fund a shotgun full of clinical trials -- not including a late-stage trial tied to a drug it bought in January -- as well as to cover costs related to recent layoffs and to continue its preclinical programs.
No comments:
Post a Comment